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pen accessAbstract Background: To ﬁnd out the cost effective antiemetic drug combination as a prophylaxis
against nausea and vomiting during regional anesthesia for cesarean section.
Methods: After the gaining of institutional ethical approval, 240 parturients scheduled for elective
cesarean delivery under spinal anesthesia were randomly allocated to receive either 2 mg granisetron
plus 8 mg dexamethasone (group II) IV immediately after clamping of the fetal umbilical cord or
2 mg midazolam plus 8 mg dexamethasone (group III) IV or placebo (group I).
Results: The use of rescue antiemetic medication, which indicates either vomiting or severe nausea,
in the post delivery period intraoperatively was 37%, 14%, 23% in group I, II and III, respectively.
These values are signiﬁcantly less than the corresponding values during the ﬁrst 24 h after surgery
which was 20%, 7%, 13%, respectively. No clinically serious adverse events were observed in any of
the groups.
Conclusion: The prophylactic use of a granisetron/dexamethasone combination is better than
midazolam/dexamethasone for reducing nausea and vomiting in patients during and after spinal
anesthesia for cesarean section.
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Nausea and vomiting during regional anesthesia for cesarean
section still remain a big problem not only for the patient only
but for the surgeon and the anesthesiologist as well. The etiol-
ogy of intraoperative nausea and vomiting is complex; it may
be attributed to surgical stimulation, hypotention, vagal stim-
ulation and uterotonic drugs. Patient demographic data and
anesthetic technique also have a role [1].
A plenty of pharmacological approaches including dopa-
mine receptor antagonists (e.g. metoclopramide), butyrophe-
nones (e.g. dropridol), antihistaminic (diphenhydramine),
anticholinergic drugs (atropine) and steroids (dexamethazone)
have been used as a prophylactic antiemetic during regional
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cause side effects such as sense of drowsiness, dystonia and
extrapyramidal signs [2].
Granisetron is selective antagonist of 5-hydroxytryptamine
type 3 (5-HT3) receptors and it is an efﬁcient antiemetic during
and after regional anesthesia for cesarean section [3,4]. A com-
bination of granisetron and dexamethasone has been reported
to be a more powerful than granisetron alone [2].
Benzodiazepines including midazolam have been reported
to be a good alternative for the usual antiemetics in controlling
persistent postoperative nausea and vomiting [5].
We hypothesized that a combination of midazolam and
dexamethazone given after cord clamping, would be effective
as granisetrone–dexamethazone combination in reducing post-
delivery and postoperative nausea and vomiting in women
undergoing cesarean delivery under regional anesthesia with
low cost.
2. Patient and methods
After the gaining of institutional ethical approval and written
informed consent from the participants, the study was per-
formed in 240 women ASA I and II (American Society of
Anesthesiologists), with uncomplicated pregnancies, who were
scheduled for elective cesarean delivery under spinal anesthe-
sia. Exclusion criteria included patients who had gastrointesti-
nal diseases, those who had a history of previous postoperative
emesis, or an antiemetic medication within 24 h before surgery.
All parturients received 1000 ml lactated Ringer’s solution IV
over 30 min before spinal injection. The subjects were allocated
randomly to three groups, using a computer-generated ran-
domization code. The group I (n= 80) received saline (pla-
cebo), while group II (n= 80) received 2 mg granisetron plus
8 mg dexamethasone IV immediately after clamping of the fe-
tal umbilical cord and group III (n= 80) received 2 mg midaz-
olam plus 8 mg dexamethasone IV immediately after clamping
of the fetal umbilical cord. The drug solutions in all groups
were prepared by one anesthesiologist and they looked identi-
cal. Another anesthesiologist, who was blinded to the study,
gave the drugs. All staff in the operating room was unaware
of the randomization code. After placement of standard mon-
itors, spinal anesthesia with 0.5% hyperbaric bupivacaine
according to height (2.6 ml for patients taller than 155 cm
and 2.4 ml for those shorter than 155 cm) was administered.
After induction of spinal anesthesia, the parturient was placed
supine with left uterine displacement and head up with slight
trendlenberg of the table to achieve adequate surgical block
(T4 sensory level) which was assessed by analgesia to pinprick
with ﬁne dental needle. Non-invasive arterial blood pressure
was measured every 3 min until the end of surgery. Supplemen-
tary oxygen 3 L/min was administered. Ringer lactate was
administered IV infusion (4 ml/kg/h) with replacement of any
ﬂuid deﬁcit or blood loss more than 1000 cc. Uterus was rou-
tinely exteriorized in all cases. Maternal hypotension (decrease
in systolic blood pressure of >10% from baseline) after spinal
anesthesia was treated aggressively with additional IV ﬂuid,
more uterine tilt, and increments of IV phenylephrine 25 lg.
After delivery of the baby, 5 U of IV oxytocin was given to
all parturient to enhance uterine contraction.
Nausea and vomiting were evaluated and recorded every
10 min intraoperatively and at 2 h, 4 h, 6 h, 12 h and 24 h post-operatively by an independent anesthetist who is blinded to
group assignment. Nausea was assessed using visual analogue
score (VAS; 0, no nausea; 10, worst imaginable nausea). An
antiemetic ‘‘rescue’’ drug (10 mg metoclopromide intrave-
nously) was administered in case of severe nausea (nausea
VAS 4 or more) or vomiting within the study period.
Data were also collected regarding the duration of surgery,
amount of phenylephrine consumed and complications (head-
ache, drowsiness, blurred vision, allergic reactions). Patient
satisfaction was evaluated and recorded based upon the whole
patient experience regarding antiemesis during the study peri-
od (10-point verbal numeric scoring system, 0 = not at all sat-
isﬁed, 10 = fully satisﬁed). Sedation was assessed in the
postanaesthetic care unit (PACU) with modiﬁed Ramsey seda-
tion score (RSS) [6] (Awake levels were: 1, patient anxious and
agitated or restless or both; 2, patient co-operative, orientated,
and tranquil; 3, patient responds to commands only. Asleep
levels were dependent on the patient’s response to a light gla-
bellar tap or loud auditory stimulus: Level 4, a brisk response;
5, a sluggish response; and 6, no response) intraoperatively and
postoperatively.
3. Statistical analysis
To test the normality of data distribution K–S (Kolmogorov–
Smirnov) test was done. Normally distributed data were sub-
jected to parametric tests.
Data values were expressed as frequency (%), means ± SD,
or medians (ranges). The analysis of the data was done to test
statistical signiﬁcant difference between groups. Differences be-
tween groups were analyzed by the analysis of variance (ANO-
VA) followed by least signiﬁcant difference (LSD) test for the
post hoc comparison. Student t-test was used to compare be-
tween two groups. Chi square test was used for qualitative data;
P is signiﬁcant if it is <0.05. A prior power analysis indicated
that 80 patients in each group would be sufﬁcient to detect a
20% reduction in the incidence of nausea and vomiting, with
a type-I error of 0.05 and a power of approximately 90%.
The statistical analysis of data done by using excel program
and SPSS program statistical package for social science version
17 (SPSS Inc., Chicago, USA).
4. Results
The three groups were not signiﬁcantly different with respect
to demographic characteristics, level of sensory block,
gestational age, phenylephrine dose and duration of surgery
(Table 1).
Nausea and vomiting were statistically signiﬁcant less in
groups II, III during operation after delivery of the fetus and
for 24 h postoperatively. Also, nausea and vomiting were sta-
tistically signiﬁcant less in group II when compared to group
III during the same period. There was no statistically signiﬁ-
cant difference between the groups in the incidence of nausea
and vomiting intraoperatively before delivery of the fetus (Ta-
ble 2). The use of antiemetic rescue was statistically signiﬁcant
high in group I when compared to group II, III during opera-
tion and postoperatively. Also parturients in group III received
statistically signiﬁcant less antiemetic rescue drug when com-
pared to group II during operation and postoperatively. Seda-
tion was statistically signiﬁcant high in groups III when
Table 1 Patients characteristics and intraoperative data.
I II III
Age (yr) 26.5 ± 3.6 24.4 ± 2.1 23.4 ± 2.7
Weight (kg) 78 ± 3.2 77 ± 4.1 79 ± 4.1
Height (cm) 167.1 ± 3.4 168.2 ± 3.1 169.2 ± 1.4
Gestational age (weeks) 38.7 ± 1.7 38.9 ± 1.6 38.8 ± 1.9
Surgery duration (min) 72.1 ± 2.8 73.3 ± 1.2 74.3 ± 2.2
Phenylephrine dose (lg) 235 ± 3.2 229 ± 3.2 224 ± 4.1
Sensory block (median, range) T4 (T2–T6) T4 (T2–T5) T4 (T1–T5)
Data are presented as mean ± standard deviation or median (range).
I = Control group, II = granisetron dexamethasone group, III = midazolam dexamethasone group.
P value < 0.05 is signiﬁcant.
This table shows no signiﬁcant differences.
Table 2 Incidence of nausea and vomiting.
Variable Group I Group II Group III
Intraoperative period
Predelivery nausea 17 (21%) 15 (19%) 16 (20%)
Predelivery vomiting 20 (25%) 21 (26%) 18 (22%)
Postdelivery nausea 16 (20%) 7 (9%)a 11 (14%)a,b
Postdelivery vomiting 19 (23%) 6 (8%)a 12 (15%)a,b
Rescue antiemetic 30 (37%) 11 (14%)a 19 (23%)a,b
Sedation score 0 (0-0) 0 (0-0) 1 (1–2)a,b
Postoperative period
Nausea(0–24 h) 25 (31%) 6 (8%)a 11 (14%)a,b
Vomiting (0–24 h) 18 (22%) 5 (6%)a 9 (11%)a,b
Rescue antiemetic 20 (25%) 7 (9%)a 13 (16%)a,b
Sedation score 0 (0–0) 0 (0–0) 0 (0–1)
Values are presented as number of patient (percentage of study
group) or median (range).
P value < 0.05 is signiﬁcant.
a Signiﬁcant when compared to group I.
b Signiﬁcant when compared to group II.
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were no statistically signiﬁcant difference between groups post-
operatively (Table 3). All Groups were statistically comparable
as regard to mean arterial blood pressure and heart rate (Fig. 1
and 2).
Patient satisfaction with PONV control was higher with the
active treatment groups (II and III) compared with group I,Table 3 Patient satisfaction and side effects.
I II II
Patient satisfaction score 5.6 ± 1.4b 8.3 ± 1.2a 8.1 ± 2.3a
Headache 4 3 4
Drowsiness 2 1 1
Facial ﬂushing 3 2 2
Bradycardia 3 4 4
Values are presented as number of patients or mean ± standard
deviation.
P value < 0.05 is signiﬁcant.
a Signiﬁcant when compared to group I.
b Signiﬁcant when compared to group II.whereas, groups II and III were comparable regarding patient
satisfaction. There was no statistically signiﬁcant difference in
the incidence of adverse effects between the three groups (Ta-
ble 3).
5. Discussion
Pregnant women are more liable for occurrence of nausea and
vomiting than nonpregnant patients, this is due to the high le-
vel of progesterone which causes smooth muscle relaxation,
decreases lower esophageal sphincter tone, decreases gastroin-
testinal motility and increases gastrin secretion [5]. Moreover,
when those pregnant women undergo spinal anesthesia for
cesarean section; an additional risk of intraoperative postdeliv-
ery emetic symptoms is added; this can be attributed to postin-
duction hypotension which may lead to brainstem hypoxia and
stimulation of vomiting center [7,8].
In this study, to avoid the inﬂuence of hypotension on the
results, rapid ﬂuid infusion, left uterine displacement, or
administration of phenylephrine were performed, so that the
difference in use of antiemetic during and after cesarean sec-
tion under spinal anesthesia can be attributed to the study drug
combination.
Granisetron is one of 5HT3 receptor antagonists which
were introduced in 1991 [9], and it is devoid of drawbacks of
traditional used antiemetics, no change in vital signs and no
interaction with concomitant used anesthetics [10].
Dexamethasone was used as effective antiemetic for cancer
patients receiving chemotherapy [11], tonsillectomy [12,13],
thyroidectomy [14], laparoscopic surgery and abdominal hys-
terectomy [15]. Glucocorticoids are known to have multiple ef-
fects on central nervous system. They have an effect on
neurotransmitter concentrations, receptor densities, signal
transduction and neurone conﬁguration [16,17]. Many recep-
tors for the glucocorticoids are found in the nucleus of the sol-
itary tract, the raphe nucleus and the area postrema. These
nuclei are reported to have marked role in regulation of emetic
symptoms [18,19].
We chose to evaluate the use of a granisetron/dexametha-
sone combination in comparison with midazolam/dexametha-
sone for reducing nausea and vomiting in patients during and
after spinal anesthesia for cesarean section. Our results showed
statistically signiﬁcant decrease for nausea and vomiting in
groups II and III when compared with group I during opera-
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Figure 2 Intraoperative heart rate of the studied groups. All Groups were statistically comparable.
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Figure 1 Intraoperative mean arterial blood pressure (mm Hg) of the studied groups.
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But, there was a statistically signiﬁcant decrease for nausea
and vomiting in group II when compared with group III dur-
ing the same period. Also, the use of rescue antiemetic drug
was statistically signiﬁcant high in group I when compared
to group II, III and in group III when compared to group II
during operation and postoperatively.
Our results are in agreement with a study showed that a
combination of granisetron and dexamethasone is more effec-
tive for controlling emetic symptoms during and after spinal
anesthesia for cesarean delivery than granisetron alone [2].
How dexamethasone enhances granisetron is not known ex-
actly, it is suspected that dexamethasone may antagonize stim-
ulation of 5-HT receptors [20,21]. Fujii and his colleagues did
not register signiﬁcant side effects of using this combination
apart from increased cost of antiemetic therapy [2].
In contrast to our result, Balki et al. [1] found that prophy-
lactic granisetron does not prevent postdelivery nausea and
vomiting during elective cesarean delivery under spinal anes-
thesia. This may be attributed to use of dexamethasone in
addition to granisetron.
In a double blind randomized study by Tarhan et al. [5], it
was reported that a subhypnotic dose of midazolam was an
effective antiemetic as a subhypnotic dose of propofol forpregnant women undergoing cesarean section under spinal
anesthesia. This is in accord with our study. Midazolam may
exert its antiemetic effect through interference with neuronal
reuptake of adenosine which will reduce synthesis, release
and postsynaptic action of dopamine at CRTZ [5,22]. Also,
it is thought that benzodiazepines including midazolam bind
to receptors on gamma amino butyric acid (GABA) – ergic
neurons which are suspected to have an inhibitory effect on
central dopaminergic pathways [5,23]. All of this beside the
anxiolytic effect of midazolam may explain its antiemetic effect
[5,24].
In our study, we suspected that addition of dexamethasone
to midazolam will increase its efﬁcacy as an antiemetic and will
be comparable with granisetron–dexamethasone combination.
But our results showed a signiﬁcant increased incidence of
emetic symptoms with midazolam–dexamethasone combina-
tion in comparison with granisetron–dexamethasone combina-
tion; beside signiﬁcant increased incidence of unwanted
sedation in a patient undergoing regional anesthesia.
In Egypt, granisetron (56 Egyptian pounds for 2 mg) and
dexamethasone. (3 Egyptian pounds for 8 mg) are much more
expensive than midazolam (3.5 Egyptian pounds for 2 mg) and
dexamethasone. However, a decision about antiemetics should
not be limited to these costs but should also consider the out-
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to occur. A cost-effective analysis, deﬁned as the cost per unit
of success was not performed in this study.
Our study has a few limitations. We did not include other
antiemetic combination rather than those used .The second
limitation is that non-pharmacological antiemetic methods
was not used. So further studies are needed.
In summary, a combination of midazolam and dexametha-
sone given after cord clamping, is not effective as granisetron–
dexamethasone combination in reducing post delivery and
postoperative nausea and vomiting in women undergoing
cesarean delivery under regional anesthesia.
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